9 Hrs
Source:
المشهد
Russia Shot Shows Promise
Russia announced that its personalized mRNA vaccine, NeoOncovac, currently intended for certain cases of melanoma, helped the first patient to receive it—a 60-year-old man—achieve the disappearance of metastases, with no new tumors detected during four months of follow-up. The vaccine is tailored to the genetic profile of each patient’s tumor and is administered alongside immunotherapy. The patient will continue to be monitored for three years. The results remain preliminary and do not establish that the vaccine is effective on a broader scale or against other types of cancer; larger studies are still needed.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)